miR‑4636 inhibits tumor cell proliferation, migration and invasion, and serves as a candidate clinical biomarker for gastric cancer

Tang,Jiaying; Hu,Ying; Zhang,Chunjie; Gong,Cuixue

doi:10.3892/ol.2020.12294

miR‑4636 inhibits tumor cell proliferation, migration and invasion, and serves as a candidate clinical biomarker for gastric cancer

Authors:
- Jiaying Tang
- Ying Hu
- Chunjie Zhang
- Cuixue Gong
View Affiliations

Affiliations: Department of Blood Transfusion, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China, Department of Blood Transfusion, Qilu Hospital Huantai Branch, Zibo, Shandong 256400, P.R. China, Clinical Laboratory, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China, Outpatient Dressing Room, Zibo Central Hospital, Zibo, Shandong 255000, P.R. China
Published online on: November 12, 2020 https://doi.org/10.3892/ol.2020.12294
Article Number: 33
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is one of the most common malignancies with a high worldwide incidence rate. The association between microRNAs (miRs) and malignancy has been widely studied in recent years. The aim of the present study was to assess the clinical value of miR‑4636 in patients with GC and its effect on the proliferation, migration and invasion of GC cells. Reverse transcription‑quantitative PCR was used to detect the expression of miR‑4636. Receiver operating characteristics curve, Kaplan‑Meier survival curve and Cox regression analyses were used to evaluate the diagnostic and prognostic value of miR‑4636. Transwell migration and MTT assays were used to assess the regulatory effects of miR‑4636 expression on the biological function of GC. The results demonstrated that the expression of miR‑4636 was significantly downregulated in GC serum and tissue samples, as well as in GC cell lines. The aberrant miR‑4636 expression was closely associated with lymph node metastasis and TNM stage, and had considerable diagnostic and prognostic significance in patients with GC. Cellular experiments revealed that the overexpression of miR‑4636 inhibited GC cell proliferation, migration and invasion, while the knockdown of miR‑4636 led to opposite effects on the biological function of GC. In summary, decreased miR‑4636 expression may serve as a biomarker for the diagnosis and prognosis of GC. Furthermore, miR‑4636 overexpression significantly inhibited GC cell proliferation, migration and invasion, indicating the potential of miR‑4636 as a therapeutic target for GC treatment.

View Figures

View References

1	Piazuelo MB and Correa P: Gastric cancer: Overview. Colomb Med (Cali). 44:192–201. 2013.PubMed/NCBI
2	Correa P: Human gastric carcinogenesis: A multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res. 52:6735–6740. 1992.PubMed/NCBI
3	Stock M and Otto F: Gene deregulation in gastric cancer. Gene. 360:1–19. 2005. View Article : Google Scholar : PubMed/NCBI
4	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
5	Wang Y, Li M, Zang W, Ma Y, Wang N, Li P, Wang T and Zhao G: MiR-429 up-regulation induces apoptosis and suppresses invasion by targeting Bcl-2 and SP-1 in esophageal carcinoma. Cell Oncol (Dordr). 36:385–394. 2013. View Article : Google Scholar : PubMed/NCBI
6	Farazi TA, Hoell JI, Morozov P and Tuschl T: MicroRNAs in human cancer. Adv Exp Med Biol. 774:1–20. 2013. View Article : Google Scholar : PubMed/NCBI
7	Lee YS and Dutta A: MicroRNAs in cancer. Annu Rev Pathol. 4:199–227. 2009. View Article : Google Scholar : PubMed/NCBI
8	Zhang L, Liu F, Fu Y, Chen X and Zhang D: MiR-520d-5p functions as a tumor-suppressor gene in cervical cancer through targeting PTK2. Life Sci. 254:1175582020. View Article : Google Scholar : PubMed/NCBI
9	Yu HY and Pan SS: MiR-202-5p suppressed cell proliferation, migration and invasion in ovarian cancer via regulating HOXB2. Eur Rev Med Pharmacol Sci. 24:2256–2263. 2020.PubMed/NCBI
10	Chen X, Zhang L, Song Q and Chen Z: MicroRNA-216b regulates cell proliferation, invasion and cycle progression via interaction with cyclin T2 in gastric cancer. Anticancer Drugs. 31:623–631. 2020. View Article : Google Scholar : PubMed/NCBI
11	Cai H, Lin H, Cao W, Sun J, Huang Y and Fang Y: The downregulation of miR-519a predicts poor prognosis and contributes to tumor progression in gastric cancer. Int J Clin Exp Pathol. 12:2496–2505. 2019.PubMed/NCBI
12	Yin S, Yang M, Li X, Zhang K, Tian J, Luo C, Bai R, Lu Y and Wang M: Peripheral blood circulating microRNA-4636/-143 for the prognosis of cervical cancer. J Cell Biochem. 121:596–608. 2020. View Article : Google Scholar : PubMed/NCBI
13	Zhang C, Zhang CD, Ma MH and Dai DQ: Three-microRNA signature identified by bioinformatics analysis predicts prognosis of gastric cancer patients. World J Gastroenterol. 24:1206–1215. 2018. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Strong VE: Progress in gastric cancer. Updates Surg. 70:157–159. 2018. View Article : Google Scholar : PubMed/NCBI
16	Cheng XJ, Lin JC and Tu SP: Etiology and prevention of gastric cancer. Gastrointest Tumors. 3:25–36. 2016. View Article : Google Scholar : PubMed/NCBI
17	Wagner AD, Unverzagt S, Grothe W, Kleber G, Grothey A, Haerting J and Fleig WE: Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. CD0040642010.PubMed/NCBI
18	Pyrhonen S, Kuitunen T, Nyandoto P and Kouri M: Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer. Br J Cancer. 71:587–591. 1995. View Article : Google Scholar : PubMed/NCBI
19	von Felden J and Villanueva A: Role of molecular biomarkers in liver transplantation for hepatocellular carcinoma. Liver Transpl. 26:823–831. 2020. View Article : Google Scholar : PubMed/NCBI
20	Pan QZ, Liu Q, Zhou YQ, Zhao JJ, Wang QJ, Li YQ, Tang Y, Gu JM, He J, Chen SP, et al: CIK cell cytotoxicity is a predictive biomarker for CIK cell immunotherapy in postoperative patients with hepatocellular carcinoma. Cancer Immunol Immunother. 69:825–834. 2020. View Article : Google Scholar : PubMed/NCBI
21	Backes C, Meese E and Keller A: Specific miRNA disease biomarkers in blood, serum and plasma: Challenges and prospects. Mol Diagn Ther. 20:509–518. 2016. View Article : Google Scholar : PubMed/NCBI
22	Liu Q, Yang W, Luo Y, Hu S and Zhu L: Correlation between miR-21 and miR-145 and the incidence and prognosis of colorectal cancer. J Buon. 23:29–35. 2018.PubMed/NCBI
23	Cai H, Lin H, Cao W, Sun J, Huang Y and Fang Y: Downregulation of miR-519a predicts poor prognosis and contributes to tumor progression in gastric cancer. Oncol Res Treat. 43:19–26. 2020. View Article : Google Scholar : PubMed/NCBI
24	Li J and Zou X: MiR-652 serves as a prognostic biomarker in gastric cancer and promotes tumor proliferation, migration, and invasion via targeting RORA. Cancer Biomark. 26:323–331. 2019. View Article : Google Scholar : PubMed/NCBI
25	Hu ML, Xiong SW, Zhu SX, Xue XX and Zhou XD: MicroRNAs in gastric cancer: From bench to bedside. Neoplasma. 66:176–186. 2019. View Article : Google Scholar : PubMed/NCBI
26	Jin W, Han H and Liu D: Downregulation miR-539 is associated with poor prognosis of gastric cancer patients and aggressive progression of gastric cancer cells. Cancer Biomark. 26:183–191. 2019. View Article : Google Scholar : PubMed/NCBI
27	Li Y, Zhou HC, Zhang Y and Huang H: MicroRNA-625-3p inhibits gastric cancer metastasis through modulating EZH2. Eur Rev Med Pharmacol Sci. 24:1177–1185. 2020.PubMed/NCBI